Ann: Motor Neurone Disease Clinical Trial Update, page-96

The year is 2025 :

Roger has progressed to super top secret confidential discussions with super interested partners. They are up to pinky promises we are led to believe.

We have opened a fourth trial centre in the USA. We have recruited 4 of the ten dogs required for the FDA registration trial. PAA expect to wrap up the overall phase 2 trial sometime within the following 12 months.

Several stellar candidates have been through screening for the CEO role. Unfortunately their stated values of shareholder return, results matter and accountability didn't fit with company values.

A recent CR was completed to cover the first proposed human cancer trial. Funds will be used to identify which cancer to target and to try find willing clinics, hopefully in a very remote and challenging part of the world....because we always like a challenge. PAA expects to get underway with the first human cancer trial sometime before 2035. Living up to the company values of little to no accountability, management have decided using broad ranging target dates allows them to deliver on this. They have announced though that they expect this to occur imminently followed by a smiley face and then a laughing with tears streaming out emoji.

Directors have taken to AGM vote a 'giving it a bloody good go' bonus for all BOD. They dispute some negative shareholder claims that this is in effect a participation award and counter claim that 'science is hard, and timelines are even harder...but we gave it a bloody good go'....

Covid is again running rampant through the population and many suffer. PAA claim that while MPL may make a difference as much clinical testing suggests, whats actually important is not spending the money raised to fund the covid human trial on the trial but rather to keep it on the balance sheet because it earns steady interest in the bank and pays wages...and that's a safe bet...remember science is risky.